Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
Won-Seog Kim(Samsung Medical Center), Hirokazu Nagai(Tokai University), Yoko Okitsu(Tohoku University Hospital), Naokuni Uike(St Mary's Hospital), Kenichi Ishizawa(Yamagata University), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Fumiko Nagahama, Yusuke Sonehara, Yasunobu Abe(National Hospital Organization Kyushu Cancer Center), Toshiki Uchida(Red Cross Hospital), Kensei Tobinai(National Cancer Center)
Cited by 1
Related Papers
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
|Journal of Clinical Oncology|2019|154
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease
|Annals of Oncology|2014|151
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
|Clinical Infectious Diseases|2015|149